Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech, received U.S. patent No. 12,350,242 titled “BINGE BEHAVIOR REGULATORS” from the USPTO.
The patent covers MEAI-based compositions using pharmaceutically acceptable salts to regulate binge behaviors and lifts Clearmind’s global portfolio to 32 granted patents, supporting programs like CMND-100 for binge-related and CNS disorders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- U.S. patent No. 12,350,242 granted for MEAI binge behavior regulators
- Intellectual property portfolio increases to 32 granted patents globally
- Patent supports development of MEAI for multiple binge behaviors
- Broader IP protection strategy for lead candidate CMND-100 and CNS pipeline
Negative
- None.
News Market Reaction – CMND
On the day this news was published, CMND declined 2.87%, reflecting a moderate negative market reaction. Argus tracked a peak move of +17.9% during that session. Argus tracked a trough of -10.6% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $138K from the company's valuation, bringing the market cap to $4.66M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 16 | Trial dosing update | Positive | -6.8% | Completed dosing for Part A of Phase I/II CMND-100 AUD trial. |
| Jun 05 | Clinical webinar | Positive | +36.8% | Announced webinar to review early CMND-100 clinical data with key investigators. |
| May 29 | IP expansion | Positive | +46.1% | Japanese patent application publication for MEAI-based depression treatment compositions. |
| May 26 | Trial advancement | Positive | +14.6% | Johns Hopkins IRB approval to advance CMND-100 Phase I/II trial to Parts B and C. |
| May 19 | Reverse split | Negative | -37.8% | 1-for-10 reverse share split to address Nasdaq minimum bid price compliance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
CMND has generally traded in line with the tone of past news, with only one recent example of a negative reaction to positive trial progress.
Regulatory & Risk Context
Reported short interest reflects a relatively modest level of bearish positioning, implying some potential for volatility but not an extreme squeeze-driven setup based on the latest data.
An effective Form F-3 shelf registers resales of shares issuable from up to $10.0M of convertible notes plus accrued interest, giving CLA Investors flexibility to convert and sell while not providing direct primary proceeds to the company.
Key Terms
neuroplastogens medical
pharmaceutically acceptable salt medical
central nervous system medical
cns medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, Canada, June 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced that it has been granted a U.S. Patent, No. 12,350,242, titled “BINGE BEHAVIOR REGULATORS”, by the United States Patent and Trademark Office (USPTO).
The patent, which refers to Clearmind’s molecule MEAI (5-methoxy-2-aminoindane), covers innovative compositions and methods utilizing a pharmaceutically acceptable salt to regulate binge behaviors, including excessive drinking, eating, and gambling.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “We are very pleased to secure this important U.S. patent, increasing our global portfolio to 32 granted patents and reinforcing our leadership in psychedelic-based therapies. We believe that this milestone directly advances our clinical programs for binge-related disorders, such as alcohol use disorder, where patients urgently need more effective options. Clearmind remains committed to expanding its robust intellectual property portfolio. We continue to build broad IP protection in major global markets for our lead candidate, CMND-100, and our broader pipeline of central nervous system (CNS) therapeutic technologies."
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its leadership in psychedelic-based therapies, advancing its clinical programs for binge-related disorders and its commitment to expanding its robust intellectual property portfolio. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
